

Special Issue

Adult Stem Cells in Aging

Message from the Guest Editor

The goal of the Special Issue “**Adult Stem Cells in Aging**” is to discuss the decline in stem cell potential as a cause of the degradation of the regenerative/homeostatic capacities that is seen in many aged and diseased tissues. This Special Issue on encourages Authors to submit their original research or review articles that bring new evidences or synthesis of the most recent and breakthrough data in the field of stem cell behavior in aging process. Topics include, but are not limited to:

- Aged stem cell phenotype: nuclear organization, transcriptional and translational regulation
- Aged stem cell niche components; stem cells in physiological and pathologic aging
- Tumor-suppressor molecules in regulation of cellular senescence
- Molecular interactions of cellular quiescence, aging, programmed death/autophagy and cancer
- Mitochondrial health and epigenetic alternations during aging in quiescent and activated stem cells
- Resistance of stem cells to pro-aging agents and rejuvenation approaches (e.g. nutrient limitation, senescence modulators)
- Diseased stem cell phenotypes and clinical relevance of delayed aging


Guest Editor

Dr. Drenka Trivanovic

Group for Hematology and Stem Cells, Institute for Medical Research, National Institute of Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia

Deadline for manuscript submissions

closed (10 March 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/71734

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).